Fexofenadine/pseudoephedrine Allergy medicine A nonsedating antihistamine with a decongestant for relief of seasonal allergic rhinitis. See Allergic rhinitis, Antihistamine.
References in periodicals archive ?
The Allegra family of allergy products, including Allegra Allergy (12 and 24 hour), Allegra-D (12 and 24 hour) and Children's Allegra (12 hour), is available without a prescription in drug, grocery, mass merchandiser and club stores nationwide.
The FDA also approved behind-the-counter sale of Allegra-D 24-hour and 12-hour extended-release tablets, which include the decongestant pseudoephedrine, for patients older than 12 years, according to the company.
Patents on Allegra and Allegra-D, a 12-hour version, expire in 2012 and 2017.
The letter from the health care plan medical director suggests that Allegra and Allegra-D, both made by Hoechst Marion Roussel, "may be appropriate alternatives" and informs the enrollee that it has notified her doctor about Allegra and Allegra-D and their relative cost to the health care plan.
The Allegra family of products provides patients with convenience and flexibility in treating their different seasonal allergy needs: Allegra 30 mg and 60 mg twice-daily; Allegra 180 mg once-daily; Allegra-D 12-Hour (fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg) Extended-Release Tablets for twice daily dosing; and Allegra-D 24 Hour (fexofenadine HCl 180 mg/ pseudoephedrine HCl 240 mg) Extended-Release Tablets for once daily dosing.
Allegra-D 24 Hour provides allergy patients with the power of once-daily Allegra (fexofenadine HCl) 180 mg, combined with 24-hour relief from nasal congestion, in a convenient, once- daily tablet.
Aventis Pharmaceuticals markets Allegra-D for the treatment of the symptoms associated with seasonal allergic rhinitis.
The Company believes it was the first applicant to file an ANDA containing a paragraph IV patent challenge with respect to the capsule and tablet products and that Barr was the first to file on all but one of the patents relating to the Allegra-D product.
Allegra-D is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older.
Food and Drug Administration (FDA) has approved a new drug application (NDA) for Aventis' new Allegra-D 24 Hour tablets (fexofenadine HCl 180 mg / pseudoephedrine HCl 240 mg), a formulation developed with aaiPharma and Osmotica Pharmaceutical.
today confirmed Aventis' submission of a new drug application (NDA) to the FDA for Aventis' Allegra-D 24 hour tablets (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg), a formulation developed with aaiPharma using a patented extended release drug delivery technology, ProSlo II(TM), developed by Osmotica.